Ballentine Partners LLC Takes Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Ballentine Partners LLC acquired a new stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 13,094 shares of the medical technology company’s stock, valued at approximately $120,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in Alphatec in the 3rd quarter valued at about $69,000. Net Worth Advisory Group purchased a new stake in shares of Alphatec during the 3rd quarter valued at approximately $76,000. Van ECK Associates Corp grew its position in shares of Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after purchasing an additional 6,998 shares in the last quarter. Tempus Wealth Planning LLC bought a new stake in shares of Alphatec during the third quarter valued at about $107,000. Finally, Atria Investments Inc boosted its holdings in Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ATEC has been the topic of a number of recent analyst reports. Needham & Company LLC raised their target price on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Barclays boosted their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.56.

Alphatec Stock Down 5.7 %

Shares of Alphatec stock opened at $11.01 on Monday. The stock has a market capitalization of $1.56 billion, a PE ratio of -8.60 and a beta of 1.41. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company has a 50-day simple moving average of $9.92 and a two-hundred day simple moving average of $8.07. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the transaction, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,208 shares of company stock worth $706,835. Insiders own 22.80% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.